Compare CGEM & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGEM | AORT |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.7M | 2.1B |
| IPO Year | 2021 | 1993 |
| Metric | CGEM | AORT |
|---|---|---|
| Price | $12.50 | $42.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $28.13 | ★ $49.36 |
| AVG Volume (30 Days) | ★ 701.9K | 262.2K |
| Earning Date | 02-26-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $422,646,000.00 |
| Revenue This Year | N/A | $15.97 |
| Revenue Next Year | N/A | $10.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.81 |
| 52 Week Low | $5.68 | $21.97 |
| 52 Week High | $13.33 | $48.25 |
| Indicator | CGEM | AORT |
|---|---|---|
| Relative Strength Index (RSI) | 67.85 | 39.43 |
| Support Level | $10.45 | $41.82 |
| Resistance Level | $12.99 | $45.41 |
| Average True Range (ATR) | 0.76 | 1.41 |
| MACD | 0.19 | -0.08 |
| Stochastic Oscillator | 86.34 | 29.26 |
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.